secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-07-09T12:05:21+00:00
Accession:  0001193125-26-299177
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement
--------------------------------------------------------------------------------

- FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.
- Statistically significant improvement observed by day 64 (p=0.023) and continued through week 24 after 12-week treatment.
- In subjects with baseline FVASI ≥0.75, FB102 showed 43.2% mean improvement (p=0.006); 58.8% achieved FVASI50, 23.5% FVASI75.
- 84% (27/32) of FB102-treated subjects improved from baseline to week 24; 0% worsened vs 27% of placebo worsened.
- FB102 demonstrated strong safety profile with only mild to moderate AEs, comparing favorably to placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/0001193125-26-299177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/d170175d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-299177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer